137 related articles for article (PubMed ID: 3064776)
1. Postmastectomy irradiation in high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group trials.
Overgaard M; Christensen JJ; Johansen H; Nybo-Rasmussen A; Brincker H; van der Kooy P; Frederiksen PL; Laursen F; Panduro J; Sørensen NE
Acta Oncol; 1988; 27(6A):707-14. PubMed ID: 3064776
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of radiotherapy in high-risk breast cancer patients: report from the Danish Breast Cancer Cooperative Group (DBCG 82) Trial.
Overgaard M; Christensen JJ; Johansen H; Nybo-Rasmussen A; Rose C; van der Kooy P; Panduro J; Laursen F; Kjaer M; Sørensen NE
Int J Radiat Oncol Biol Phys; 1990 Nov; 19(5):1121-4. PubMed ID: 2254100
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B.
Dombernowsky P; Brincker H; Hansen M; Mouridsen HT; Overgaard M; Panduro J; Rose C; Axelsson CK; Andersen J; Andersen KW
Acta Oncol; 1988; 27(6A):691-7. PubMed ID: 3064774
[TBL] [Abstract][Full Text] [Related]
4. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials.
Rutqvist LE; Cedermark B; Glas U; Johansson H; Rotstein S; Skoog L; Somell A; Theve T; Askergren J; Friberg S
Int J Radiat Oncol Biol Phys; 1989 Mar; 16(3):629-39. PubMed ID: 2493433
[TBL] [Abstract][Full Text] [Related]
6. Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial.
Overgaard M; Nielsen HM; Tramm T; Højris I; Grantzau TL; Alsner J; Offersen BV; Overgaard J;
Radiother Oncol; 2022 May; 170():4-13. PubMed ID: 35288227
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.
Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Andersson M; Kamby C; Knoop AS;
Cancer; 2010 May; 116(9):2081-9. PubMed ID: 20186830
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
10. Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group.
Wallgren A; Bernier J; Gelber RD; Goldhirsch A; Roncadin M; Joseph D; Castiglione-Gertsch M
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):649-59. PubMed ID: 8690630
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C.
Mouridsen HT; Rose C; Overgaard M; Dombernowsky P; Panduro J; Thorpe S; Rasmussen BB; Blichert-Toft M; Andersen KW
Acta Oncol; 1988; 27(6A):699-705. PubMed ID: 3064775
[TBL] [Abstract][Full Text] [Related]
12. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
Johansen J; Overgaard J; Overgaard M
Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
[TBL] [Abstract][Full Text] [Related]
13. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials.
Overgaard M; Nielsen HM; Overgaard J
Radiother Oncol; 2007 Mar; 82(3):247-53. PubMed ID: 17306393
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
Pritchard KI; Paterson AH; Fine S; Paul NA; Zee B; Shepherd LE; Abu-Zahra H; Ragaz J; Knowling M; Levine MN; Verma S; Perrault D; Walde PL; Bramwell VH; Poljicak M; Boyd N; Warr D; Norris BD; Bowman D; Armitage GR; Weizel H; Buckman RA
J Clin Oncol; 1997 Jun; 15(6):2302-11. PubMed ID: 9196144
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial.
Andersson M; Kamby C; Jensen MB; Mouridsen H; Ejlertsen B; Dombernowsky P; Rose C; Cold S; Overgaard M; Andersen J; Kjaer M
Eur J Cancer; 1999 Nov; 35(12):1659-66. PubMed ID: 10674010
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
[TBL] [Abstract][Full Text] [Related]
17. Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience.
Velez-Garcia E; Moore M; Vogel CL; Marcial V; Ketcham A; Bartolucci A; Liu C; Smalley R
Breast Cancer Res Treat; 1983; 3 Suppl():S49-60. PubMed ID: 6367861
[TBL] [Abstract][Full Text] [Related]
18. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.
Mouridsen HT; Rose C; Brincker H; Thorpe SM; Rank F; Fischerman K; Andersen KW
Recent Results Cancer Res; 1984; 96():117-28. PubMed ID: 6396765
[No Abstract] [Full Text] [Related]
20. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
